ALAUNOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 USD | +3.81% |
|
-5.22% | +2.78% |
Financials (USD)
| Sales 2022 | 2.92M | Sales 2023 | 5K | Capitalization | 16.98M |
|---|---|---|---|---|---|
| Net income 2022 | -37M | Net income 2023 | -35M | EV / Sales 2022 | 46.5 x |
| Net cash position 2022 | 19.55M | Net cash position 2023 | 6.06M | EV / Sales 2023 | 2,184 x |
| P/E ratio 2022 |
-3.74
x | P/E ratio 2023 |
-0.48
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alaunos Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +3.81% | ||
| 1 week | -5.22% | ||
| 1 month | -15.50% | ||
| 3 months | -51.23% | ||
| 6 months | +5.31% | ||
| Current year | +2.78% |
1 week
1.00
1.15
1 month
1.001.42
Current year
0.983.29
1 year
0.667.96
3 years
0.6660.15
5 years
0.66108.75
10 years
0.66223.95
| Managers | Title | Age | Since |
|---|---|---|---|
Dale Hogue
CEO | Chief Executive Officer | 54 | Dec. 28 |
| Director of Finance/CFO | 62 | 21-02-16 | |
Melinda Lackey
ADM | Chief Administrative Officer | 47 | 21-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jaime Vieser
BRD | Director/Board Member | 54 | 20-12-15 |
Holger Weis
CHM | Chairman | 61 | 20-12-15 |
Robert Postma
BRD | Director/Board Member | 70 | 21-02-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.09 | +3.81% | 12,293 |
| 24-05-30 | 1.05 | -1.87% | 34,256 |
| 24-05-29 | 1.07 | -0.93% | 63,214 |
| 24-05-28 | 1.08 | -6.09% | 45,379 |
| 24-05-24 | 1.15 | +6.48% | 36,724 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.78% | 17.45M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.67% | 12.27B |
- Stock Market
- Equities
- TCRT Stock
